Merck returns antifungal rights to Scynexis
Research Triangle Park, N.C. — Merck (NYSE: MRK)is returning all of the rights of an antifungal compound to Scynexis after the drug giant decided it did not want to pursue that compound anymore....
Please Log In to add a comment.
Latest for Insiders
- NetSuite exec: Look for many new jobs in Durham after $200M Bronto buy
- Lenovo recalls 166,000 ThinkPad battery packs due to fire hazard
- Finalists in 'Full Steam Ahead Awards:' Competition is hot
- The closing of Raleigh's last B&B and the failure of government
- CEO: Marketing puts some sizzle in the Cree brand
- IBM, SAS top 'Magic Quadrant'in multichannel campaign management report
- IBM tells McCrory it opposes NC Religious Freedom Restoration Act
- NC's venture industry reports best first quarter in 8 years
- Report: Venture funding surges in NC thanks to life science deals
- Job growth study: Raleigh No. 2 in tech, No. 1 in STEM